Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared To Pembrolizumab Monotherapy In Pd-L1-Positive Advanced Nsclc In Harmoni-2 Study Conducted By Akeso In China - SMMT News | Rallies
Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared To Pembrolizumab Monotherapy In Pd-L1-Positive Advanced Nsclc In Harmoni-2 Study Conducted By Akeso In China
Ivonescimab monotherapy demonstrates statistically significant overall survival benefit compared to pembrolizumab monotherapy in PD-L1-positive advanced NSCLC in HARMONI-2 study conducted by Akeso in China.
SMMT•
